|Description||TDI-4161 is a novel alphaVbeta3 antagonist developed for osteoporosis therapy. It inhibits alphaVbeta3-dependent cell adhesion without inducing high-affinity ligand binding or exposure of the epitope for MAb AP5 (both dependent on the beta3 PSI domain).|
|Brife Description||alphaVbeta3 antagonist, osteoporosis therapy|
|Synonyms||TDI-4161; TDI 4161; TDI4161|
|Application||potential osteoporosis therapy|
|Current Developer||Rockefeller University|
BMS-505130 is a selective serotonin transport inhibitor with Ki of 0.18 nM. Ki value for binding to the norepinephrine is 4.6 mM and for dopamine transporters i...
6-Azauracil inhibits enzymes in nucleoside synthesis and depletes the intracellular GTP/UTP pool. It is being used to identify mutations in transcriptional elon...
HMR 1031 is a potent and specific integrin α4β1 or very late antigen 4 (VLA-4) receptor antagonist binding to vascular cell adhesion molecule-1 (VCAM-1) and fib...
MMK 1 is a potent and selective human formyl peptide receptor FPR2 agonist (EC50 = 1, 2 and > 10 000 nM at mFRP2, hFPR2 and hFPR1 respectively). Some findings s...
Secretin (human) is a gastrointestinal peptide hormone that stimulates pancreatic and biliary secretion. Secretin (human) is thought to play a role in the regul...
Hydrocortisone is a corticosteroid increases blood sugar through gluconeogenesis to suppress the immune system.
Astragalus polysaccharide is one kind of biological macromolecule extracted from Astragalus. It has antiviral activities.
Non-competitive, low affinity NMDA receptor antagonist. Displays antitussive and neuroprotective effects. Active in vivo.